Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi to acquire rights to develop, commercialize aficamten
Sanofi scoops up China rights to Cytokinetics’ heart disease med ahead of approval decision
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. | As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL) for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) in Greater China.
Sanofi To Buy Rights To Develop Cytokinetics' Aficamten In Greater China From Corxel
Cytokinetics, Inc.(CYTK), a late-stage, specialty cardiovascular biopharmaceutical company, Friday announced that French drug major
Cytokinetics stock rises on Sanofi's rights acquisition
Investing.com -- Shares of Cytokinetics (NASDAQ: CYTK ), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ: SNY) will acquire exclusive rights to develop and commercialize aficamten in Greater China, a move that underscores the drug's potential in treating hypertrophic cardiomyopathy (HCM).
Sanofi to buy China rights to Cytokinetics lead asset
Cytokinetics (NASDAQ:CYTK) announced Friday that Sanofi (NASDAQ:SNY) would buy exclusive rights to its lead candidate, aficamten, in Greater China from its partner, Corxel Pharmaceuticals. The company didn’t disclose the financial terms of the agreement between but said it remains on track to receive up to $150M in milestone payments and low-to-high teens on aficamten sales from the French drugmaker.
Sanofi to acquire rights to develop, commercialize aficamten from Corxel
Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel
2d
on MSN
Why Cytokinetics Stock Was a Nearly 5% Winner Today
California-based biotech Cytokinetcs ( CYTK 4.56%) finished the trading week in style, as its stock price outperformed many ...
20d
on MSN
Cytokinetics' application for aficamten accepted by FDA
Cytokinetics (NASDAQ:CYTK) said the FDA has accepted its New Drug Application for aficamten for the treatment of obstructive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
MLB's stolen base king dies
Vows to rename Denali
US fighter jet shot down
Taxpayers to get up to $1,400
Drops out of Senate race
Mass exodus of players
Biden signs funding bill
Miller to join DOGE panel
Social Security bill approved
China: US ‘playing with fire'
Warns on Panama Canal
Blake Lively sues Baldoni
Reverses Ohio layoffs
US ambassador to Italy
US kills ISIS leader
New rules for self-driving
RFK Stadium bill passed
Top NYPD officer resigns
US hits Houthi sites
100 salmonella cases linked
Brazil bus crash: 38 dead
8 convicted in Paty murder
Zepbound OK'd for apnea
To wind down operations
Russian fuel depot targeted
MO abortion ban blocked
NBA fines Celtics coach
Proposes contract changes
Nic Claxton fined $25K
Special envoy to the UK
Moore receives Bronze Star
Speeds to $62M debut
'Die Hard 2' actor dies
Feedback